Unknown

Dataset Information

0

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.

ABSTRACT:

SUBMITTER: Ramasamy K 

PROVIDER: S-EPMC9708638 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.

Ramasamy Karthik K   Iqbal Gulnaz G   Brouwer Richard R   Stalker Victoria V   Akhtar Salma S   Varghese Sherin S   Lindsay Jindriska J   Schey Stephen S   Drayson Mark M   Dunn Janet J  

Blood cancer journal 20221129 11

Similar Datasets

Unknown Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
| S-EPMC5980148 | biostudies-literature
Unknown Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.
| S-EPMC10652744 | biostudies-literature
Unknown Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
| S-EPMC3924931 | biostudies-literature
Unknown Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.
| S-EPMC3880441 | biostudies-literature
Unknown Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
| S-EPMC4758383 | biostudies-literature
Unknown Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma.
| S-EPMC11386351 | biostudies-literature
Unknown Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation.
| S-EPMC7248497 | biostudies-literature
Unknown The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
| S-EPMC4891075 | biostudies-literature
Unknown The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan.
| S-EPMC8880219 | biostudies-literature
Unknown Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
| S-EPMC6201242 | biostudies-literature